Taiwan News

Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CHARLESTOWN, Mass., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company”), a life sciences company developing precision genetic medicines for neuromuscular and ...

Muscle regeneration hindered by missing protein in rare muscular dystrophy, study shows

For more than two decades, researchers at the University of Basel, Switzerland, have been investigating a severe form of ...
Stocktwits on MSN

Capricor Therapeutics Stock Sparks Retail Frenzy As Traders Hail ‘Best Data’ Ahead Of DMD Data Readout

In July, the FDA refused to approve Capricor’s application for Deramiocel for the treatment of cardiomyopathy associated with ...

‘Savor the Cause,’ a fundraiser to benefit Michael’s Cause, raises 16K for muscular dystrophy

STATEN ISLAND, N.Y. — In the “Big Heart” department, Mike DiLeo, executive chef at Max’s Esca, played host to “Savor the ...

UPSHER-SMITH LAUNCHES KYMBEE™ (DEFLAZACORT) TABLETS FOR THE TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY

Upsher-Smith Laboratories, LLC (Upsher-Smith) today announced the launch of KYMBEE™ (deflazacort) Tablets, indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients 5 years of age ...
The Manila Times

Solid Biosciences Receives FDA Rare Pediatric Disease Designation for SGT-212 Dual Route of Administration Gene Therapy for Friedreich’s Ataxia

SGT-212 has been granted FDA Rare Pediatric Disease and Fast Track designations - - SGT-212 is the only dual route gene therapy in development to treat Friedreich’s ataxia - CHARLESTOWN, Mass., Dec.